Trastuzumab Deruxtecan Outperforms Trastuzumab Emtansine in DESTINY-Breast03 Follow-UpDecember 8th 2022
Trastuzumab deruxtecan both significantly improved overall survival and yielded progression-free survival that was 4 times greater than trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.
Benefit-Risk Profile of Trastuzumab/Pertuzumab With FLOT Regimen Comes Into Question in HER2-positive Gastric CancerDecember 1st 2022
Trastuzumab and pertuzumab with a chemotherapy regimen of fluorouracil, leucovorin, oxaliplatin, and docetaxel increased response, and high-grade toxicity, in patients with HER2-positive gastric or gastroesophageal junction cancer.
HRD, BRCA Status May Inform PARP Inhibitor Suitability in Advanced Ovarian CancerNovember 12th 2022
During the 40th Annual Chemotherapy Foundation Symposium, Eirwen M. Miller, MD, evaluated the safety and efficacy profiles of different PARP inhibitor therapies for patients with advanced ovarian cancer.
Updates in Lung Cancer Screening Criteria Increase African American Patient ParticipationJuly 6th 2022
The expansion of screening criteria is an important step in decreasing lung cancer screening disparities in high-risk populations. Efforts to expand community outreach, overcome logistical barriers, and facilitate screening adherence must still be made, experts say.
Venetoclax/Obinutuzumab Continues to Show Efficacy in Unfit Patients with CLLJune 30th 2022
An updated safety and efficacy analysis of the ongoing CLL14 trial showed that venetoclax plus obinutuzumab continues to be an effective treatment for patients with chronic lymphocytic leukemia and coexisting conditions.
Patritumab Deruxtecan Produces Early Responses in Advanced NSCLC Regardless of Variant Genomic AlterationsJune 17th 2022
Regardless of other identified driver genomic alterations, patients with heavily pretreated, advanced, non–small cell lung cancer achieved encouraging responses with patritumab deruxtecan.
Investigational CAR T-Cell Therapy, Obecabtagene Autoleucel, Is Poised to Fill Unmet Need in Relapsed/Refractory B-ALLMarch 22nd 2022
Investigators hope that the novel obecabtagene autoleucel, a second-generation CAR T-cell therapy may fill an unmet need by representing a durable treatment option for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Lenvatinib/Pembrolizumab Combo Continues to Show Benefit in Advanced Endometrial CancerNovember 21st 2021
A presentation at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting shared updated findings on the efficacy of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer.
Balstilimab Zalifrelimab Combination Yields Promising Results in Recurrent/Metastatic Cervical CancerSeptember 23rd 2021
A phase 2 trial presented at the 2021 ESMO Annual Congress showed that Balstilimab plus Zalifrelimab induced superior response rates, duration of responses, and overall survival in patients with recurrent/metastatic cervical cancer.
Copanlisib Plus Rituximab May Be ‘Viable Option’ Across Indolent Non-Hodgkin LymphomaJuly 16th 2021
More data are needed regarding the duration of response associated with this combination to make it a “mainstream” treatment option for patients, according to an expert from the University of Michigan Rogel Cancer Center.